These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19545504)

  • 1. Interspecies extrapolation in environmental exposure standard setting: A Bayesian synthesis approach.
    Jones DR; Peters JL; Rushton L; Sutton AJ; Abrams KR
    Regul Toxicol Pharmacol; 2009 Apr; 53(3):217-25. PubMed ID: 19545504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene.
    Covington TR; Robinan Gentry P; Van Landingham CB; Andersen ME; Kester JE; Clewell HJ
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):1-18. PubMed ID: 16901594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards quantitative uncertainty assessment for cancer risks: central estimates and probability distributions of risk in dose-response modeling.
    Kopylev L; Chen C; White P
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):203-7. PubMed ID: 17905499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
    Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models.
    Hack CE
    Toxicology; 2006 Apr; 221(2-3):241-8. PubMed ID: 16466842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
    Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
    Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard.
    Toft N; Innocent GT; Gettinby G; Reid SW
    Prev Vet Med; 2007 May; 79(2-4):244-56. PubMed ID: 17292499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCMC for hidden Markov models incorporating aggregation of states and filtering.
    Rosales RA
    Bull Math Biol; 2004 Sep; 66(5):1173-99. PubMed ID: 15294422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in exposure assessment: the impact on the practice of health risk assessment and epidemiological studies.
    Nieuwenhuijsen M; Paustenbach D; Duarte-Davidson R
    Environ Int; 2006 Dec; 32(8):996-1009. PubMed ID: 16875734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence.
    Ades AE
    Stat Med; 2003 Oct; 22(19):2995-3016. PubMed ID: 12973783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian bivariate meta-analysis of diagnostic test studies using integrated nested Laplace approximations.
    Paul M; Riebler A; Bachmann LM; Rue H; Held L
    Stat Med; 2010 May; 29(12):1325-39. PubMed ID: 20101670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models for estimating bayes factors with applications to phylogeny and tests of monophyly.
    Suchard MA; Weiss RE; Sinsheimer JS
    Biometrics; 2005 Sep; 61(3):665-73. PubMed ID: 16135017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data cloning: easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods.
    Lele SR; Dennis B; Lutscher F
    Ecol Lett; 2007 Jul; 10(7):551-63. PubMed ID: 17542934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian adjustment for covariate measurement errors: a flexible parametric approach.
    Hossain S; Gustafson P
    Stat Med; 2009 May; 28(11):1580-600. PubMed ID: 19226564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification.
    Chou WC; Lin Z
    Environ Int; 2019 Aug; 129():408-422. PubMed ID: 31152982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach to probabilistic risk assessment in municipal playgrounds.
    Iribarren I; Chacón E; De Miguel E
    Arch Environ Contam Toxicol; 2009 Jan; 56(1):165-72. PubMed ID: 18427709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring heterogeneity in tumour data using Markov chain Monte Carlo.
    de Gunst MC; Dewanji A; Luebeck EG
    Stat Med; 2003 May; 22(10):1691-707. PubMed ID: 12720305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.